Recombinant Adeno-Associated Virus

Creative Biolabs manifests as a world-leading expert in recombinant adeno-associated virus (rAAV) development and provides our clients with reliable products in order to meet their various research needs. Taking advantage of the well-established recombinant virus platform, various AAV serotypes and engineered strategies are available for clients to support their projects. We will apply rigorous criteria that have been established for rAAV production to assure their quality for every gene therapy study.

To date, the rAAV is mainly used in gene therapy to deliver DNA to target cells and has been shown to be safe and effective in preclinical and clinical settings. As a non-pathogenic and actively investigated gene therapy vehicles, rAAV vectors have proven to be highly efficient in gene delivery to a wide variety of cell types, even in the body. A number of AAV serotype products are available at Creative Biolabs, including AAV2, AAV5, AAV8, and AAV9 serotype vectors with distinct tissue-tropism, and long-term transgene expression. Through rationally design and optimization, various AAV serotype vectors are capable of targeting specific tissues and organs, which further expands their therapeutic landscape. To date, about 162 Phase I/II/III clinical trials have proven the safety of rAAV vectors and clinical efficacy has also been achieved in at least 6 human diseases.

We also provide advanced adeno-associated virus vector construction services from design, purification, titration, to toxicity and safety determination.

Should you need further information, please feel free to contact us by E-mail for a quote and further discussion with our scientists.